From: Potential biological therapies for severe preeclampsia: a systematic review and meta-analysis
Reference | Population | Dose | Blood pressure (mmHg) | Proteinuria (g/day) | Gestational age at delivery (weeks) | Pregnancy prolongation (days) | |||||
---|---|---|---|---|---|---|---|---|---|---|---|
AT | Control | AT | Control | AT | Control | AT | Control | AT | Control | ||
D’Angelo, 2016 [22] | Pregnant women diagnosed with PE before 30WG (n = 38) | 3000 IU/daily of AT for 7 days or less until delivery | Placebo, 1% glycine, for 7 days or less until delivery | Diagnosis: 2.28 ± 2.31 Pre-partum:4.02 ± 3.60 | Diagnosis: 2.31 ± 1.68 Pre-partum: 4.58 ± 4.28 | Median: 4.5 Range: 1–55 | Median:3.5 Range: 1–57 | ||||
Maki, 2000 [20] | Pregnant women diagnosed with PE between 24WG and 35WG (n = 133) | 3000 IU/daily of AT for 7 days or less until delivery | Placebo, 582 mg human albumin, once daily for 7 days | 34.1 ± 3.2** | 33.0 ± 2.7 | Prolonged gestation by 6.5 compared to placebo ** | N/A | ||||
Sameshima, 2008 [9] | Pregnant women diagnosed with PE before 32WG (n = 82) | 3000 IU/daily of AT for 7 days or less until delivery | Placebo, 582 mg human albumin, once daily for 7 days | 24–27: n = 5 28–29: n = 2 30–31: n = 11 32–33: n = 10 34≤: n = 11* (compared to control at 34≤) | 24–27: n = 1, 28–29: n = 11 30–31: n = 9 32–33: n = 16 34≤: n = 4 | ||||||
Sibai, 2017 [23] | Pregnant women diagnosed with PE between 23WG and 30WG (n = 120) | rhAT 250 mg loading dose followed by a continuous infusion 2000 mg/24 h | Placebo, identical to AT dose except with saline | 28.8 ± 2.7 | 11.2 ± 14.6 | 16.1 ± 20.9 | |||||
Paternoster, 2007 [25] | Pregnant women diagnosed with PE between 24WG and 30WG (n = 88) | 5000 IU on day 1, then received a dose that was calibrated to achieve a plasma level of a minimum of 120% of baseline value for the next 6 days. | Placebo | Unknown. States that pregnancy was prolonged in AT group. | N/A | ||||||
Paternoster, 2004 [24] | Pregnant women diagnosed with PE between 24 and 33WG (n = 23) | Received one dose of AT sufficient to reach a plasma AT activity of at least 80% of the normal as well as 3000 U/day for 5 days | One dose of AT sufficient to reach a plasma AT activity of at least 80% of the normal | Baseline: 1.56 Change: 5.14 | Baseline: 3.07 Change: 2.85 | 28.76 ± 3.83 | 29.35 ± 3.10 | 6 ± 2.1 | 3.5 ± 3.4 | ||
Nakabayashi, 1999 [26] | Pregnant women with PE before 32WG (n = 29) | 1500 U/day of AT concentrate plus 5000 U/day of heparin was administered intravenously for 7 days | 5000 U/day of heparin for 7 days | Systolic: 145.3 ± 3.2** Diastolic: 110.3 ± 4.9 | Systolic: 161.4 ± 2.9 Diastolic: 106.1 ± 4.5 | 32.1 ± 2.5 | 31.8 ± 2.3 | ||||
Kobayashi, 2003 [21] | Pregnant women diagnosed with PE between 24WG and 36WG (n = 29) | 1500 U/day of AT concentrate plus 5000 U/day of heparin was administered intravenously for 7 days | 5000 U/day of heparin for 7 days | 32.3 ± 3.1 | 29.8 ± 3.7 | ||||||
Shinyama, 1996 [28] | Pregnant rats fed high salt diet (n = 36) | Low dose group: 60 U/kg/day for 10 days; High dose group: 300 | Placebo, 3 mL/kg/day of saline for 10 days | High dose: 233*; Low dose: 236 | At 15–17 DG: 249mmHg | High (300 U/kg/day): 32*; Low (60 U/kg/day): 51 | At 17–19 DG: 93.5 (mg/kg/24h) |